Samimagham, 20 patient famotidine late treatment RCT: 33% shorter hospitalization [p=0.04] and no change in recovery [p=1] https://c19p.org/samimagham
copied to clipboard
The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A phase III randomised clinical trial
et al., Research Square, doi:10.21203/rs.3.rs-462937/v1 (Preprint)
Very small RCT with 20 patients in Iran, showing shorter hospitalization time with famotidine treatment. There was no mortality or ICU admission. Famotidine 160mg four times a day. IRCT20200509047364N2.
|
hospitalization time, 33.3% lower, relative time 0.67, p = 0.04, treatment 10, control 10.
|
|
risk of no recovery, no change, RR 1.00, p = 1.00, treatment 5 of 10 (50.0%), control 5 of 10 (50.0%), >50% CT lung involvment.
|
|
risk of no recovery, 50.0% lower, RR 0.50, p = 0.37, treatment 3 of 10 (30.0%), control 6 of 10 (60.0%), NNT 3.3, no improvement in cough.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Samimagham et al., 4/27/2021, Single Blind Randomized Controlled Trial, placebo-controlled, Iran, Middle East, preprint, 6 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.